凉血解毒汤对小鼠阴道上皮细胞增殖的抑制作用

为观察小鼠服用凉血解毒汤后对其阴道上皮细胞有丝分裂的影响,将小鼠分别灌胃凉血解毒汤大、中、小剂量组、克银I号方组和生理盐水组,MTX腹腔注射.2周后取阴道标本石蜡包埋,HE染色,显微镜下计数有丝分裂指数.结果表明有上述药物组成的复方与MTX作用相似,均能显著抑制小鼠阴道上皮细胞的有丝分裂,但中药组的抑制作用弱于MTX组(P<0.05).     

白疕胶囊对银屑病小鼠模型的干预机制研究

目的观察白疕胶囊(土鳖虫,穿心莲,珍珠母,乌梢蛇)对银屑病小鼠阴道上皮有丝分裂及尾部鳞片表皮颗粒层的影响及其量效关系,并探讨其作用机制。方法采用雌激素灌胃刺激小鼠阴道上皮组织增生的方法制作银屑病小鼠动物模型,直接利用小鼠尾部鳞片模型,给予白疕胶囊不同剂量(0.72 g/kg,0.36 g/kg),甲氨蝶呤(MTX)2 mg/kg及生理盐水(NS)进行干预,14 d后计数小鼠阴道上皮有丝分裂指数和小鼠尾部颗粒层鳞片数。结果与对照组相比,白疕胶囊的各剂量组及MTX组对小鼠阴道上皮基底细胞有丝分裂均具有不同程度的抑制作用(P0.05);且均能促进鼠尾鳞片表皮颗粒层的形成(P0.05),从而促进表皮的正常分化。结论白疕胶囊可通过抑制上皮细胞有丝分裂和促进表皮颗粒层生成发挥治疗银屑病的作用。     

土槐煎剂治疗寻常型银屑病实验研究

为探讨土槐煎剂治疗寻常型银屑病的作用机制。对雌雄性小鼠各30只,分别采用灌饲中药土槐煎剂高低浓度组和生理盐水组,对比观察土槐煎剂对小鼠阴道上皮细胞增殖及鼠尾鳞片表皮分化的影响。结果土槐煎剂对小鼠阴道上皮细胞有丝分裂有显著的抑制作用(P<0.01),对小鼠尾部鳞片表皮的颗粒形成有显著的促进作用(P<0.01)。实验结果从病理上证实土槐煎剂治疗寻常型银屑病的疗效是可靠的。     

中药顽银灵对实验小鼠影响的研究

目的探讨中药顽银灵对实验小鼠急性中毒试验、抑瘤试验和阴道上皮细胞增殖的影响。方法将顽银灵给予小鼠灌胃其最大耐受量为266.4g生药/kg,相当于人用药量的80倍,观察其毒性反应;观察顽银灵对小鼠可移植性肿瘤S180(肉瘤)的生长有无抑制作用;观察中药对实验小鼠阴道上皮细胞增殖的抑制作用。结果该中药以最大浓度,最大容积给药,均未见到任何毒性反应,对小鼠肿瘤S180的生长有微弱的抑制作用;对小鼠的阴道上皮细胞增殖有明显的抑制作用。结论中药顽银灵安全无毒,有微弱的抑制肿瘤作用,有明显的抗有丝分裂作用,提示具有抗银屑病作用。     

辣椒素对银屑病小鼠模型的作用

目的　研究辣椒素对银屑病小鼠模型的作用机制。方法　采用小鼠尾部鳞片表皮模型和阴道上皮细胞有丝分裂模型 ,观察辣椒素对表皮细胞分化及上皮细胞有丝分裂的影响。结果　辣椒素能促进小鼠尾部鳞片表皮颗粒层形成 (P <0 .0 1) ,显著抑制小鼠阴道上皮细胞的有丝分裂 (P <0 .0 1)。结论　辣椒素对银屑病小鼠模型的作用可能与促进表皮细胞正常分化和抑制表皮细胞增殖有关。     

凉血四根提取物对实验性鼠阴道上皮细胞过度增殖的影响

目的通过动物实验来观察凉血四根提取物治疗寻常性银屑病的可能机制及量效关系,为临床应用提供实验依据。方法通过腹腔注射乙烯雌酚造成小鼠阴道上皮细胞过度增殖来模拟银屑病病理改变,用凉血四根提取物灌胃治疗11d,取阴道上皮,通过病理切片观察该提取物对银屑病模型鼠阴道上皮细胞过度增殖的影响。结果灌胃治疗后病理结果显示:凉血四根提取物对小鼠阴道上皮细胞有丝分裂有明显的抑制作用。结论凉血四根提取物可能通过抑制小鼠阴道上皮细胞过度增殖起到治疗银屑病的作用,且疗效与剂量相关。     

TNF-α对小鼠银屑病模型的实验研究

为了研究TNF-α对银屑病两种动物实验模型的作用,采用小鼠阴道上皮细胞有丝分裂模型及小鼠尾部鳞片表皮模型,以甲氨碟呤为阳性对照,评价TNF-α对细胞有丝分裂和颗粒细胞层的作用.结果显示TNF-α对小鼠阴道上皮细胞的有丝分裂、小鼠尾部鳞片表皮的颗粒层形成均无明显影响.提示TNF-α对银屑病皮损的影响是一个极及其复杂的过程.     

中药白疕合剂对实验性银屑病小鼠模型的影响

目的观察中药白疕合剂对银屑病模型小鼠阴道上皮细胞有丝分裂及白细胞介素8(interleukin-8,IL-8)产生的影响,并探讨其作用机制。方法将50只实验性银屑病模型小鼠随机分为5组,连续用药灌胃4周后,采用小鼠阴道组织HE染色法观察白疕合剂对上皮细胞有丝分裂指数的影响,采用酶联免疫吸附试验(enzyme-linked immunosorbent assay,ELISA)法检测各组小鼠血清中IL-8的水平,并与10只正常小鼠作对比。结果白疕合剂能显著抑制银屑病小鼠模型阴道上皮有丝分裂,降低血清中IL-8的产生(与对照组比较,P0.01)。结论白疕合剂可能通过抑制上皮细胞有丝分裂,降低血清IL-8的产生发挥治疗银屑病的作用。     

应用动物模型观察中草药复方内服治疗银屑病的机理

银屑病是临床常见、病因不明而又难治的皮肤病 ,其表皮病理的特点主要包括颗粒层减少和角化不全两方面。药物如能促进鼠尾鳞片表皮生成颗粒层 ,说明其可能改变银屑病表皮的角化不全 ,从而具有治疗作用 ;药物如能抑制小鼠阴道上皮基底细胞的有丝分裂 ,说明其亦可能抑制银屑病表皮的增生[1] 。据此 ,我们将临床上治疗银屑病的有效的 3种中药复方制成流浸膏 ,观察其对小鼠鼠尾鳞片颗粒层细胞及对小鼠阴道上皮基底细胞有丝分裂的影响 ,以探讨中药内服治疗银屑病的机理。1　 3种中药复方对鼠尾鳞片表皮颗粒层细胞形成的影响作者单位 :1山东中医药…     

不同剂量凉血活血复方对小鼠上皮细胞增殖、表皮细胞分化、血浆内皮素1及血清可溶性E-选择素的影响

目的 探索中药凉血活血复方治疗银屑病的可能机制及考察量效关系，为临床应用提供实验依据。方法 用小鼠实验模型观察不同剂量凉血活血复方对小鼠阴道上皮有丝分裂、鼠尾鳞片表皮颗粒层形成、血浆内皮素1(ET-1)和血清可溶性E-选择素(sE—selectin)的影响。结果 中、高剂量凉血活血复方对表皮增殖、分化及血浆ET-1和血清sE-selectin均有明显调节作用。低剂量组仅对表皮增殖有抑制作用。结论 凉血活血复方可能通过阻断多个发病环节起到治疗银屑病的作用，这种作用与剂量有关。     

丹参注射液对小鼠鼠尾表皮细胞分化的影响及其作用机制研究

目的探索丹参注射液治疗银屑病的可能机制及量效关系,为临床应用提供实验依据。方法采用小鼠鼠尾鳞片表皮实验模型,不同组别的小鼠以丹参注射液或甲氨喋呤腹腔注射,观察其对鼠尾表皮颗粒细胞生成的作用;计算脾指数、胸腺指数(mg/10g体重);并用ELISA法测定各组小鼠血清肿瘤坏死因子-α(TNF-α)、白细胞介素-2(IL-2)、干扰素-γ(IFN-γ)和血清可溶性E-选择素(sE-selectin)水平的变化。结果中、高剂量丹参注射液组和MTX组可显著促进小鼠鼠尾表皮颗粒层细胞的形成并抑制血清TNF-α,IL-2,IFN-γ,sE-selectin的表达,中、高剂量组与MTX组差异无显著性(P>0.05)。低剂量组仅促进表皮颗粒层细胞形成并抑制sE-selectin的表达,与MTX组差异有高度显著性(P<0.01)。各组均对小鼠脾指数、胸腺指数无影响,MTX组可降低小鼠脾指数,显著降低小鼠胸腺指数。结论丹参注射液可能通过阻断多个发病环节起到治疗银屑病的作用,这种作用与剂量有关。     

薄膜封包对慢性皮炎小鼠模型表皮增生的影响

目的探讨薄膜封包对慢性皮炎小鼠模型表皮增生的影响。方法以0.01%佛波酯(TPA)涂搽小鼠皮肤,造慢性皮炎表皮增生模型,应用非通透性膜封包,采用组织病理及免疫组化法观察表皮增生改变及增殖细胞核抗原(PCNA)的表达。结果 TPA保鲜膜组和TPA基质组,表皮厚度(μm)分别为89.94±14.34,84.28±20.64,t=2.51;PCNA阳性标记率(%)分别为20.12±1.04,19.85±1.68,t=0.52,两者比较差异无统计学意义(P>0.05)。结论利用0.01%佛波酯(TPA)反复涂擦小鼠背部可以复制慢性皮炎模型;增殖细胞核抗原在慢性皮炎动物模型中表达明显增高;薄膜封包对慢性皮炎小鼠模型表皮增生没有明显调节作用。     

Safety and efficacy profile of oral cyclosporine vs oral methotrexate vs oral acitretin in palmoplantar psoriasis: A hospital based prospective investigator blind randomized controlled comparative study

Palmoplantar psoriasis (PPP) is a variant of psoriasis which affects only 5% body surface area, but has a devastating impact on affected individual's quality of life. There are few studies assessing efficacy of individual drugs, and few comparative studies of efficacy of two drugs in the literature, however randomized control trial comparing all three drugs against each other has not been done. A total of 75 patients of PPP were enrolled for study and randomly divided into three groups A, B, C of 25 each and assigned for treatment with cyclosporine (CSA) (2.5‐5 mg/kg/d), methotrexate (MTX)(7.5‐15 mg/week), and acitretin (ACT) (25‐50 mg/d), respectively. Modified psoriasis area and severity index (PASI), psoriasis severity scale, visual analogue scale, physician global assessment, and PPQOL were used for monitoring response to therapy and improvement in quality of life up to end of study, and thereafter monthly follow‐up was done to find duration of remission for next 90 days. Side effects if any were recorded. There was a statistically significant difference in modified PASI for CSA, MTX, and ACT. The mean modified PASI at baseline was 12.8 ± 4.8 for CSA, 12.57 ± 3.8 for MTX, and 11.92 ± 3.28 for ACT (P = .75). Mean modified PASI reduced to 2.91 ± 1.8 for CSA, 6.57 ± 2.2 for MTX, and 4.7 ± 2.2 for ACT at week 5 (P = <.01). Mean modified PASI further reduced to 0.095 ± 0.35 for CSA, 2.12 ± 1.4 for MTX, and 0.78 ± 0.97 for ACT at end of study (P = <.01). However, average duration of remission was 9 weeks for ACT group, followed by 6.47 and 3 weeks for CSA and MTX group, respectively. Adverse events were comparatively more in ACT group as compared to MTX and CSA groups. PPP affects quality of life tremendously and warrants systemic treatment for the same. CSA provides fastest resolution of lesions and have highest efficacy. MTX and ACT have similar efficacy, but ACT provides longer duration of remission.     

Efficacy and safety of mycophenolate mofetil vs. methotrexate for the treatment of chronic plaque psoriasis

Background Methotrexate (MTX) is a well‐known systemic drug for moderate to severe chronic plaque psoriasis. Recently, mycophenolate mofetil (MMF) has been recommended for psoriasis. Objective To compare the efficacy and safety of MMF vs. MTX for the treatment of chronic plaque psoriasis. Methods Thirty‐eight consecutive patients with Psoriasis Area and Severity Index (PASI) >10 were randomly assigned for 12 weeks of treatment with either MTX (18 patients; initial dose, 7.5 mg/week) or MMF (20 patients; dose; 2 g/day) and were followed for 12 weeks after discontinuing the treatment. The differences between the two groups were analysed at the end of treatment and follow‐up comparing with baseline values. Results After 12 weeks of treatment, the mean ± SD score for the PASI decreased from 16.46 ± 5.29 at baseline to 3.17 ± 2.35 among 15 patients treated with MTX, whereas the score decreased from 17.43 ± 7.42 to 3.97 ± 5.95 among 17 patients treated with MMF (P > 0.05). Twelve weeks after discontinuing the treatment, the scores were 4.77 ± 3.52 and 5.94 ± 4.27, respectively (P > 0.05). PASI ‐75 were achieved in 58.8% of patients in MMF group and 73.3% in MTX group (P > 0.05). Three months after discontinuing the treatment, PASI‐75 remained in 33.3% of patients in MMF and 53.3% of MTX group (P > 0.05). Both drugs were well tolerated and side‐effects were minor and transient. Conclusions No significant differences in efficacy were found between MTX and MMF groups. MMF may represent a good alternative for the treatment of psoriasis in patients who are unable to take MTX or other available drugs due to contraindication or toxicity.     

Efficacy and safety of systemic methotrexate in two fixed doses of 10 mg or 25 mg orally once weekly in adult patients with severe plaque-type psoriasis: a prospective, randomized, double-blind, dose-ranging study

Background. Methotrexate (MTX) is the ‘gold‐standard’ drug for the treatment of severe psoriasis. In the absence of any consensus on an optimum dose of MTX for psoriasis, there is wide variation in prescribing patterns between dermatologists, resulting in variable or delayed therapeutic effects. Aim. To identify the most effective fixed single weekly dose of oral MTX with acceptable side‐effects in the treatment of severe plaque‐type psoriasis. Methods. This was a prospective, randomized, double‐blind, parallel‐group, dose‐ranging study, which enrolled 60 patients of both genders (aged 18–62 years) with severe chronic plaque‐type psoriasis. Patients were randomly assigned to one of two groups: group A was treated with MTX 10 mg once weekly, and group B was treated with 25 mg MTX once weekly. The main outcome measure was change in Psoriasis Area and Severity Index (PASI) between the two groups from baseline to 12 weeks. Results. Of the 60 patients, 51 (85%) completed the 12‐week study. At the end of the study, 24 patients (92.3%) in the MTX 25 mg group had achieved a 75% reduction in PASI (PASI 75) from baseline, compared with 18 patients (72%) in the MTX 10 mg group (P > 0.05). Mean time in weeks to achieve PASI 75 was significantly shorter in the MTX 25 mg group (7.92 ± 1.91) than in the MTX 10 mg group (9.47 ± 2.29) (P < 0.05). In addition, 20 patients (69%) in the MTX 25 mg group achieved 100% reduction in PASI compared with 9 patients (30%) in the MTX 10 mg group within 12 weeks of the study period (P < 0.01). Adverse effects were generally mild, and were noted in 43.1% of the 51 patients who completed the study, with no significant difference in frequency between the two groups, although they were less severe in the 10 mg group. Conclusions. MTX 25 mg is an effective dose as monotherapy for the treatment of severe psoriasis, whereas the 10 mg dose is slow to act and less effective, but has a less severe side‐effect profile.     

Efficacy of oral methotrexate (MTX) monotherapy vs oral MTX plus narrowband ultraviolet light B phototherapy in palmoplantar psoriasis

Palmoplantar psoriasis (PPP) is a chronic, inflammatory dermatosis of the palms and/or soles with significant morbidity. It is notoriously difficult to treat and unresponsive to traditional topical agents. We aim to compare the effect of oral methotrexate (MTX) monotherapy vs MTX plus narrowband ultraviolet light B (NB‐UVB) in the treatment of recalcitrant PPP. This was a comparative clinical trial involving 90 patients of PPP. Eligible patients were randomly assigned to one of the two treatment groups. We aim patients in group A received 10 mg oral MTX weekly, and patients in group B received oral MTX 10 mg weekly and NB‐UVB sessions twice weekly for 12 weeks. There was a statistically significant difference in reduction of modified PPP Area Severity Index (m‐PPPASI) of patients in MTX plus NB‐UVB at week 12. The mean m‐PPPASI at week 12 was 3.66 ± 2.11 in MTX plus NB‐UVB group and 6.51 ± 2.04 in MTX only group (P < .001). Marked improvement (m‐PPPASI 75) was achieved in 20 (44.44%) patients in MTX plus NB‐UVB group compared with 6 (13.3%) in MTX monotherapy group (P < .001). Combination of MTX and NB‐UVB phototherapy helps to attain a better clinical response (reduction in m‐PPPASI score) than MTX monotherapy in the treatment of recalcitrant PPP.     

乳酸菌阴道胶囊治疗老年性阴道炎临床疗效分析

目的:探讨乳酸菌阴道胶囊治疗老年性阴道炎的临床价值及优越性.方法:将104例老年性阴道炎患者随机分为观察组和对照组,观察组给予乳酸菌阴道胶囊治疗,对照组给予甲硝唑栓治疗,观察两组患者临床疗效、阴道PH值变化及复发率等相关情况.结果:观察组总有效率为94.23%,明显高于对照组的71.15%,组间比较有显著差异(P<0.05);两组患者治疗后阴道 PH值均较治疗前有明显下降(P<0.05或 P<0.01);观察组治疗后阴道 PH值明显低于对照组(P<0.05);观察组复发率为1.92%,明显低于对照组的19.23%,组间比较有显著差异(P<0.01).结论:乳酸菌阴道胶囊治疗老年性阴道炎具有疗效好、复发率低、使用简单等诸多优点,可作为目前治疗老年性阴道炎的一种较佳治疗方案.